公开(公告)号：US20240358807A1

公开(公告)日：2024-10-31

申请号：US18489222

申请日：2023-10-18

Applicant: Cognate Bioservices, Inc. ,  Northwest Biotherapeutics, Inc. ,  The Regents of the University of California ,  RevImmune, Inc.

Inventor： Marnix Leo Bosch ,  James Kelly Ganjei ,  Linda F. Powers ,  Linda M. Liau ,  Robert M. Prins

IPC: A61K39/00 ,  A61F7/00 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  C07K16/28

CPC classification number: A61K39/0011 ,  A61F7/00 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61K38/2046 ,  A61K38/2086 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61N5/10 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55527

Abstract: A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.

公开(公告)号：US20150202291A1

公开(公告)日：2015-07-23

申请号：US14534158

申请日：2014-11-05

Applicant: COGNATE BIOSERVICES, INC. ,  NORTHWEST BIOTHERAPEUTICS ,  The Regents of the University of California ,  RevImmune, Inc.

Inventor： Marnix Leo Bosch ,  James Kelly Ganjel ,  Linda F. Powers ,  Linda M. Liau ,  Robert M. Prins

IPC: A61K39/395 ,  A61F7/00 ,  A61K35/17 ,  A61N5/10 ,  A61K39/00 ,  A61K45/06

CPC classification number: A61K39/0011 ,  A61F7/00 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61K38/2046 ,  A61K38/2086 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55527 ,  A61N5/10 ,  C07K16/2818 ,  A61K2300/00

Abstract: A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.

Abstract translation: 包括一个或多个循环和/或剂量的检查点抑制剂和治疗剂的组合治疗方案，以任一次序或基本上同时顺序地，可以在一些受试者中治疗癌症和/或可以启动， 增加，增强或延长免疫细胞的活性和/或数量，抗肿瘤免疫应答的功效或肿瘤的医学上有益的反应。

公开(公告)号：US20150273033A1

公开(公告)日：2015-10-01

申请号：US14533879

申请日：2014-11-05

Applicant: COGNATE BIOSERVICES, INC. ,  NORTHWEST BIOTHERAPEUTICS ,  The Regents of the University of California ,  Revlmmune, Inc.

Inventor： Marnix Leo Bosch ,  James Kelly Ganjel ,  Linda F. Powers ,  Linda M. Liau ,  Robert M. Prins

IPC: A61K39/00 ,  A61K39/395

CPC classification number: A61K39/0011 ,  A61F7/00 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61K38/2046 ,  A61K38/2086 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55527 ,  A61N5/10 ,  C07K16/2818 ,  A61K2300/00

Abstract: The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.

Abstract translation: 本公开至少部分地从精液认识到至少包括一个或多个检查点抑制剂和治疗剂的组合治疗方案，其顺序地以任一次序或基本上同时进行，可以更有效地 在某些受试者中治疗癌症和/或可引发，增强，增强或延长免疫细胞的活性和/或数量，或由肿瘤引起的医学上有益的反应。

公开(公告)号：US20240382572A1

公开(公告)日：2024-11-21

申请号：US18615955

申请日：2024-03-25

Applicant: Cognate Bioservices, Inc. ,  Northwest Biotherapeutics, Inc. ,  The Regents of the University of California ,  RevImmune, Inc.

Inventor： Marnix Leo Bosch ,  James Kelly Ganjei ,  Linda F. Powers ,  Linda M. Liau ,  Robert M. Prins

IPC: A61K39/00 ,  A61F7/00 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  C07K16/28

Abstract: The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.

公开(公告)号：US20160151422A1

公开(公告)日：2016-06-02

申请号：US15018731

申请日：2016-02-08

Applicant: Cognate BioServices, Inc.

Inventor： James B. Mitchell, II

IPC: A61K35/28 ,  G01N33/569 ,  C12N5/0775

CPC classification number: A61K35/28 ,  A61K2035/124 ,  C12N5/0647 ,  C12N5/0667 ,  C12N2509/00 ,  G01N33/56966 ,  G01N2333/70596

Abstract: The present invention relates to a method of isolating hematopoietic stem cells from adipose tissue. The method yields a notably high number of CD34+, ALDHbr and/or ABCG2-expressing cells, comprising hematopoietic stem cells, permitting the use of the cells with no or minimal expansion.

Abstract translation: 本发明涉及从脂肪组织分离造血干细胞的方法。 该方法产生显着高数量的包含造血干细胞的CD34 +，ALDHbr和/或ABCG2表达细胞，允许使用没有或最小扩增的细胞。